Navigation Links
Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
Date:3/13/2008

ance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Contact:

Helle Husted,

Sr. Director, Investor Relations,

T: +45-33-44-77-30,

M: +45-25-27-47-13,

E: hth@genmab.com

Contact for PDL:

Kathleen Rinehart (Media)

+1-650-454-2543

kathleen.rinehart@pdl.com

Jean Suzuki (Investors)

+1-650-454-2648

jean.suzuki@pdl.com

Stock Exchange Release no. 09/2008


'/>"/>
SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
2. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
3. Medarex Announces Completion of Sale of Shares in Genmab A/S
4. Genmabs Financial Calendar for 2008
5. Genmab Reaches Milestones in Ofatumumab Collaboration
6. Genmab Announces HuMax-CD32b Pre-Clinical Program
7. Roche Files IND for Second Genmab Antibody
8. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
9. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
10. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
11. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...   Niagara Thermal Products is proud to announce ... LLC ("B3") as the critical thermal component supplier in ... Army Corps of Engineers.  B3 has developed the only ... and destroys VOCs and other chemical pollutants, allergens and ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... 15, 2014 ­ RedBrick Health , a fast-growing ... today announces that EmblemHealth , the ... is now providing the RedBrick Compass health assessment, combined ... all of its members. EmblemHealth is among the first ...
(Date:1/15/2014)... 15, 2014 A study has been launched ... Formula 1 track could help to tackle the problem of ... Stowhealth (a GP surgery based in Stowmarket) and academics at ... Telemetry technology, which is inspired by equipment used ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... International,Corporation (Nasdaq: PRXL ) announced today it ... Conference in New York, NY. James,Winschel, Senior Vice ... formal presentation on PAREXEL at 1:20 p.m. EST ... be available under the "Upcoming Events" section,on PAREXEL,s ...
... Inc. (Nasdaq: SVNT ) today announced the submission ... (FDA) seeking approval to,market pegloticase in the United States ... includes data from both the six-month,placebo controlled Phase 3 ... Extension (OLE) study. The data set includes 101 patients ...
... MEETING, Pa., Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP; ... present at the following conferences:, 1. ... in New York. Management is currently scheduled ... on Monday, November 3. A webcast of this presentation will ...
Cached Biology Technology:PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference 2Savient Submits Biologics License Application (BLA) for pegloticase 2Savient Submits Biologics License Application (BLA) for pegloticase 3Savient Submits Biologics License Application (BLA) for pegloticase 4BMP Sunstone Announces Participation in November Investor Conferences 2
(Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
(Date:7/9/2014)... Researchers from The Cancer Genome Atlas (TCGA) Research ... cancer-causing pathway in lung adenocarcinoma, the most common ... changes may expand the number of possible therapeutic ... greater number of patients with treatable mutations because ... already exist. , TCGA is jointly funded and ...
(Date:7/9/2014)... may be able to cope with the rising salinity of ... Arctic today is best known for its tundra and polar ... to 38 million years ago during what is known as ... huge temperate forest with brackish water, home to a variety ... and giant tortoises. Much of what is known about the ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... known already for its role in schizophrenia ... according to a report in todays advance on-line issue ... Deaconess Medical Center (BIDMC), the study further suggests that ... diagnostic marker and therapeutic supplement for the treatment of ...
... which glows under ultraviolet light have shown that up ... cleaned. Their findings, published in BioMed Centrals journal, BMC ... bacteria Clostridium difficile (C. difficile) linger in the loo ... Michelle Alfa and a team of scientists from Manitoba, ...
... technology, DALLAS, May 7 An innovator ... will provide its proven public key,infrastructure to the ... on machine readable travel documents (MRTDs),-- also known ... nearly 23 million,citizens by the end of 2008., ...
Cached Biology News:A new gene trigger for pregnancy disorder identified 2UV lotion lights the way to cleaner facilities 2Entrust, Hewlett Packard Partner to Deploy Taiwanese ePassports, Authenticate Biometric Data 2Entrust, Hewlett Packard Partner to Deploy Taiwanese ePassports, Authenticate Biometric Data 3
... Perhaps sheer in-house demand is causing shortages in ... antibody. This can cause unwanted distractions, problems and ... for your hard work and endeavour! Bring us ... and market it internationally. We work under ISO ...
... Neuromedin U-23 (rat) - Diluted Antiserum for ... Neuromedin U-23 (rat) Immunology Products, Host: ... For our corresponding peptide and ... please see Neuromedin U-23 (rat) (H-9295) and ...
... Topoisomerase I from vaccinia virus is ... both positive and negative superhelical turns (also ... closed DNA. The product of the reaction ... fewer positive or negative superhelical turns. DNA ...
...
Biology Products: